Search

Your search keyword '"Eli Lilly and Co. -- Management"' showing total 384 results
Start Over Descriptor "Eli Lilly and Co. -- Management"
384 results on '"Eli Lilly and Co. -- Management"'

2. Market Action: it's a quiet start to the week

Subjects
Eli Lilly and Co. -- Management, Pharmaceutical industry, Company business management, Business, News, opinion and commentary
Abstract

Market Action: it's a quiet start to the week, unlike panicked atmosphere last Monday. Treasury yields have erased small overnight losses and are fractionally richer on the session in spite [...]

Published
2024

3. Frontrunners in Next-Generation Radiotherapeutics: New radiotherapeutic agents are making headway in hard-to-treat cancers

Author

Barton, Cheryl

Subjects
Eli Lilly and Co. -- Management, Cancer, Radiotherapy, Pharmaceutical industry, Company business management, Business, Pharmaceuticals and cosmetics industries
Abstract

Ariceum Therapeutics, a private biotechnology company, based in Germany, is focused on developing novel drugs for systemic targeted radiation therapy (STRT) for hard-to-treat cancers. The name Ariceum is an anagram [...]

Published
2023

4. Eli Lilly Visits DePauw University, Offering Students Insight and Opportunities - The DePauw

Author

Huynh, Vinh

Subjects
Eli Lilly and Co. -- Management, College students, Internship programs, Pharmaceutical industry, Career opportunity, Company business management, News, opinion and commentary, Sports and fitness, DePauw University -- Management
Abstract

Byline: Vinh Huynh DePauw University students had a unique opportunity on Monday, Sept. 16, 2024, as the global pharmaceutical company Eli Lilly visited our campus. The event featured many activities, [...]

Published
2024

5. Eli Lilly opens new innovation centre in Boston Seaport

Subjects
Alexandria Real Estate Equities Inc. -- Management, Eli Lilly and Co. -- Management, Diabetes therapy, Ports, Company business management, Business
Abstract

M2 EQUITYBITES-August 13, 2024-Eli Lilly opens new innovation centre in Boston Seaport (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Eli Lilly and Company (Lilly) (NYSE: LLY), a global medicine company, has officially opened [...]

Published
2024

6. Adcytherix Launches with EUR 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates

Subjects
Eli Lilly and Co. -- Management, Biological products, Viral antibodies, Antibodies, Pharmaceutical industry, Company business management, Banking, finance and accounting industries, Business
Abstract

Adcytherix Launches with EUR 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates Vision is to establish a leading ADC developer to treat high unmet need diseases such [...]

Published
2024

7. Alveolus Bio Enters Into Strategic Collaboration with BiomEdit

Subjects
Elanco Animal Health -- Management, Eli Lilly and Co. -- Management, Consortia, Consortium, Company business management, Business, News, opinion and commentary
Abstract

CAMBRIDGE, Mass. and BIRMINGHAM, Ala., Dec. 8, 2023 /PRNewswire/ -- Alveolus Bio today announced a strategic scientific collaboration with BiomEdit, an emerging animal health biotechnology company leveraging microbiome science and [...]

Published
2023

8. FDA Approves Lilly's Zepboundtm (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

Subjects
United States. Food and Drug Administration -- Management, Eli Lilly and Co. -- Management, Obesity -- Drug therapy, Drug approval, Type 2 diabetes -- Drug therapy, Pharmaceutical industry, Hypertension -- Drug therapy, Company business management, General interest, News, opinion and commentary, Obesity Action Coalition -- Management
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepboundtm (tirzepatide) injection, the first [...]

Published
2023

9. FDA Approves Lilly's Zepbound(TM) (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

Subjects
United States. Food and Drug Administration -- Management, Eli Lilly and Co. -- Management, Obesity -- Drug therapy, Dextrose, Glucose, Drug approval, Type 2 diabetes -- Drug therapy, Company business management, Business, News, opinion and commentary, Obesity Action Coalition -- Management
Abstract

Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP [...]

Published
2023

10. ProQR Therapeutics NV Management Call - Final

Subjects
Eli Lilly and Co. -- Management, Executives, RNA, Company business management, Business
Abstract

Presentation SARAH CUE KIELY, VP OF IR & CORPORATE COMMUNICATIONS, PROQR THERAPEUTICS N.V.: Thank you, operator, and good day, everyone. We appreciate you joining the call. I'm Sarah Kiely, Vice [...]

Published
2022

11. VETmAb Biosciences' Bow-Wow Biz: BIOTECH: Startup Developing Antibodies for Pets

Author

Clemetson, Jeff

Subjects
Eli Lilly and Co. -- Management, Biotechnology, Monoclonal antibodies, Pharmaceutical industry, Company business management, Business, Business, regional
Abstract

In the best way possible, biotechnology is going to the dogs - and San Diego startup VETmAb Biosciences, Inc. is a leader in bringing it to them. VETmAb Biosciences is [...]

Published
2023

12. Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update

Author

Tobe, Sheldon W., Stone, James A., Anderson, Todd, Bacon, Simon, Cheng, Alice Y.Y., Daskalopoulou, Stella S., Ezekowitz, Justin A., Gregoire, Jean C., Gubitz, Gord, Jain, Rahul, Keshavjee, Karim, Lindsay, Patty, L'Abbe, Mary, Lau, David C.W., Leiter, Lawrence A., O'Meara, Eileen, Pearson, Glen J., Rabi, Doreen M., Sherifali, Diana, Selby, Peter, Tu, Jack V., Wharton, Sean, Walker, Kimberly M., Hua-Stewart, Diane, and Liu, Peter P.

Subjects
Merck & Company Inc. -- Management, Bayer AG -- Management, Eli Lilly and Co. -- Management, Sanofi S.A. -- Management, Canadians, Evidence-based medicine, Hypertension, Type 2 diabetes, Diabetes therapy, Pharmaceutical industry, Blood glucose, Company business management, Health, Canadian Cardiovascular Society -- Management, University of Toronto -- Management
Abstract

The Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) is a nationally endorsed guideline process, targeting primary care health care practitioners. The C-CHANGE guideline is a composite of nine of Canada's [...]

Published
2018
Full Text
View/download PDF

13. Data on Type 2 Diabetes Reported by Researchers at Eli Lilly and Company (Improved Glycaemic and Weight Management Are Associated With Better Quality of Life In People With Type 2 Diabetes Treated With Tirzepatide)

Subjects
Eli Lilly and Co. -- Management, Medical research, Medicine, Experimental, Diabetes therapy, Glycosylated hemoglobin, Type 2 diabetes -- Care and treatment, Weight loss -- Care and treatment, Pharmaceutical industry, Company business management, Health
Abstract

2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Nutritional and Metabolic Diseases and Conditions - Type [...]

Published
2023

14. Healthcare Technology Management Global Market Report 2023

Subjects
Allscripts Healthcare Solutions Inc. -- Management, Eli Lilly and Co. -- Management, athenahealth Inc. -- Management, Information technology -- Management, Medical equipment, Computer software industry, Computer services industry, Physiological apparatus, Pharmaceutical industry, Company business management, Computer services industry, General interest, News, opinion and commentary
Abstract

New York: ReportLinker has issued the following news release: Reportlinker.com announces the release of the report 'Healthcare Technology Management Global Market Report 2023' - https://www.reportlinker.com/p06433302/?utm_source=GNW , Januarynx Medical Systems Inc., [...]

Published
2023

15. Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies

Subjects
Novartis AG -- Management, Eli Lilly and Co. -- Management, Sofinnova Partners -- Management, Fibrosis, Venture capital, Venture capital companies, Pharmaceutical industry, Company business management, Venture capital, General interest, News, opinion and commentary
Abstract

CAMBRIDGE: Mediar Therapeutics has issued the following news release: Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, [...]

Published
2023

16. Academy Asset Management Announces Its Initial Cohort of Clients

Subjects
Comcast Corp. -- Management, Eli Lilly and Co. -- Management, Cable television broadcasting industry, Military personnel, Financial services industry, Disabled veterans, Pharmaceutical industry, Company business management, Financial services industry, Business, Business, international
Abstract

NEW YORK -- Academy Asset Management, an SEC registered investment adviser and certified disabled veteran-owned and operated business, is pleased to announce the initial cohort of clients supporting the first [...]

Published
2022

17. Lilly to begin rollout of Tempo(r) Personalized Diabetes Management Platform

Subjects
Eli Lilly and Co. -- Management, Diabetes therapy, Hypoglycemic agents, Type 2 diabetes, Diabetics, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary, Basaglar (Medication), Humalog (Medication), Lyumjev (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) will begin rollout of its first connected platform, the Tempo(r) Personalized Diabetes Management [...]

Published
2022

18. Eli Lilly to begin rollout of Tempo Personalised Diabetes Management Platform in US

Subjects
Eli Lilly and Co. -- Management, Diabetes therapy, Self-care, Health, Type 2 diabetes, Company business management, Biotechnology industry
Abstract

Centralised experience supports diabetes self-management through medication reminders, education resources and insulin dose logging Eli Lilly and Company will begin rollout of its first connected platform, the Tempo Personalised Diabetes [...]

Published
2022

19. Lilly to begin rollout of Tempo Personalized Diabetes Management Platform

Subjects
Eli Lilly and Co. -- Management, Diabetes therapy, Health care industry, Hypoglycemic agents, Blood sugar, Blood sugar monitoring, Type 2 diabetes, Health care industry, Company business management, Business, News, opinion and commentary, Basaglar (Medication), Humalog (Medication), Lyumjev (Medication)
Abstract

Centralized experience supports diabetes self-management through medication reminders, education resources and insulin dose logging Data shared through platform interface may help healthcare providers make data-driven decisions[sup.Ø ]about care for adults [...]

Published
2022

20. Capsida Signs Partnership to Develop Medicines: The firm also recently announced a new CFO

Author

Fine, Howard

Subjects
Eli Lilly and Co. -- Management, Pharmaceutical industry, Company business management, Business, Business, regional
Abstract

Thousand Oaks-based gene therapy company Capsida Therapeutics Inc. has signed a multi-year partnership deal with a subsidiary of pharma giant Eli Lilly and Co. to develop genetic medicines for serious [...]

Published
2023

21. Studies from Eli Lilly and Company Provide New Data on Breast Cancer [Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current ...]

Subjects
Eli Lilly and Co. -- Management, Women's health, Cancer research, Epidermal growth factors, Pharmaceutical industry, Breast cancer -- Care and treatment, Company business management, Health, Women's issues/gender studies
Abstract

2020 NOV 26 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on breast cancer. According to news originating from Welwyn Garden [...]

Published
2020

22. Eli Lilly, DexCom announce joint program for diabetes management

Subjects
Eli Lilly and Co. -- Management, Health care industry, Type 2 diabetes, Diabetes therapy, Pharmaceutical industry, Health care industry, Company business management, Business, News, opinion and commentary, Lyumjev (Medication)
Abstract

Eli Lilly (LLY) and DexCom (DXCM) announced a joint program for U.S. healthcare providers, or HCPs, about Lilly's new rapid-acting mealtime insulin Lyumjev, now available in U.S. pharmacies, and Dexcom [...]

Published
2020

23. STRATEGIC RISK MANAGEMENT FRAMEWORK: OCTOBER 2020

Subjects
Eli Lilly and Co. -- Management, Risk management, Pharmaceutical industry, Company business management, Risk management, Banking, finance and accounting industries, Business
Abstract

TABLE OF CONTENTS Section 1: Introduction Section 2: Problem Statement Section 3: Key Elements 3.1 Liquidity and Capital 3.2 Risk Governance and Processes 3.3 Identifying and Assessing Emerging Risks 3.4 [...]

Published
2020

24. The Worldwide Pain Management Drugs Industry is Expected to Reach $99.9 Billion by 2030

Subjects
Bayer AG -- Management, Bristol-Myers Squibb Co. -- Management, Boehringer Ingelheim GmbH -- Management, Eli Lilly and Co. -- Management, Abbott Laboratories (Abbott Park, Illinois) -- Management, Pain -- Care and treatment, Analgesics, Company business management, General interest, News, opinion and commentary
Abstract

Dublin: Research and Markets has issued the following news release: The 'Global Pain Management Drugs Market, By Drug Class, By Indication, By Pain Type, By Drug Type, By Distribution Channel, [...]

Published
2022

25. PIPELINE WATCH: High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch

Author

Salzman, Sony

Subjects
Merck & Company Inc. -- Management, Pfizer Inc. -- Management, Eli Lilly and Co. -- Management, Monoclonal antibodies, Marketing, Pharmaceutical industry, Melanoma, Pain management, Biological products industry, Company business management, Business, Health care industry, Orkambi (Medication), Xolair (Medication), Opdivo (Medication), Advair Diskus (Medication), Symbicort (Medication), Kalydeco (Medication), Spiriva (Medication), Keytruda (Medication), Breo Ellipta (Medication)
Abstract

With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. It shouldn't come as a surprise, then, that [...]

Published
2018

26. Altoida Joins Digital Medicine Society's (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Predictive Biomarkers

Subjects
Eli Lilly and Co. -- Management, Societies, Augmented Reality, Alzheimer's disease -- Drug therapy, Associations, institutions, etc., Biological markers, Pharmaceutical industry, Company business management, Business, Business, international
Abstract

WASHINGTON -- Altoida, a pioneer in non-invasive brain health measurement and neurological disease diagnostics using AI and augmented reality (AR), today announced it has joined the Digital Medicine Society's (DiMe) [...]

Published
2022

27. Cognito Therapeutics Joins Digital Medicine Society's (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Clinical Measures

Subjects
Eli Lilly and Co. -- Management, Societies, Alzheimer's disease -- Drug therapy, Associations, institutions, etc., Pharmaceutical industry, Company business management, Business, Business, international
Abstract

CAMBRIDGE, Mass. -- Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced it has joined the Digital Medicine Society's (DiMe) Alzheimer's Disease and Related Dementias [...]

Published
2022

28. Reports Summarize Carcinomas Study Results from Eli Lilly and Company (Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United ...)

Subjects
Eli Lilly and Co. -- Management, Physical fitness, Pharmaceutical industry, Cancer metastasis -- Drug therapy, Esophageal cancer -- Drug therapy, Physicians, Adenocarcinoma, Carcinoma, Editors, Company business management, Health
Abstract

2020 JAN 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Oncology - Carcinomas are presented in a new report. [...]

Published
2020

29. Lilly to integrate Dexcom CGM into personalised diabetes management system

Subjects
DexCom Inc. -- Management, Eli Lilly and Co. -- Management, Diabetes therapy, Health care industry, Blood sugar monitoring, Type 2 diabetes, Pharmaceutical industry, Health care industry, Company business management, Pharmaceuticals and cosmetics industries
Abstract

Eli Lilly and Company has announced a global commercialisation agreement to integrate DexCom, Inc products into Lilly's personalised diabetes management system, currently in development to advance the treatment of diabetes. [...]

Published
2019

30. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline

Author

Morales, Alvaro, Bebb, Richard A., Manjoo, Priya, Assimakopoulos, Peter, Axler, John, Collier, Christine, Elliott, Stacy, Goldenberg, Larry, Gottesman, Irv, Grober, Ethan D., Guyatt, Gordon H., Holmes, Daniel T., and Lee, Jay C.

Subjects
Eli Lilly and Co. -- Management, Testosterone, Pharmaceutical industry, Company business management, Health
Abstract

Testosterone deficiency syndrome, also known as late-onset hypogonadism, is a clinical and biochemical syndrome that can occur in men in association with advancing age. The condition is characterized by deficient [...]

Published
2015
Full Text
View/download PDF

31. Highlights of the past 35 years in San Diego business

Subjects
Hybritech Inc. -- Management, Eli Lilly and Co. -- Management, Pension funds, Pharmaceutical industry, Company business management, Business, Business, regional
Abstract

1980 San Diego Trolley Incorporated is founded; and the $18 million Seaport Village opens on the downtown San Diego waterfront, with stores, restaurants, rides and other attractions. 1981 Hybritech, San [...]

Published
2015

32. Dr. Erdal Bozdogan joins Immunicom as its General Manager in Turkey

Subjects
Takeda Pharmaceutical Company Ltd. -- Management, Eli Lilly and Co. -- Management, Abbott Laboratories (Abbott Park, Illinois) -- Management, Pharmaceutical industry, Company business management, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Dr. Erdal Bozdogan has recently joined Immunicom, Inc., a clinical-stage biotech pioneering non-pharmaceutical immunotherapies, as its General Manager in Turkey. Dr. Bozdogan brings more than 22 years of [...]

Published
2021

33. The Executive Women's Forum on Information Security, Risk Management & Privacy Elects Three Powerhouse Women to its Board of Advisors

Subjects
Eli Lilly and Co. -- Management, Women executives, Privacy, Consultants, Risk management, Pharmaceutical industry -- Access control, Company business management, Risk management, Privacy issue, Business, general
Abstract

FLEMINGTON, N.J. (PRWEB) November 02, 2021 The Executive Women's Forum on Information Security, Risk Management, and Privacy (EWF) is excited to announce that Brenda Bjerke, Sr Directory, Cybersecurity, Target, Jane [...]

Published
2021

34. The Executive Women's Forum on Information Security, Risk Management & Privacy Elects Three Powerhouse Women to its Board of Advisors

Subjects
Eli Lilly and Co. -- Management, Women executives, Privacy, Consultants, Risk management, Pharmaceutical industry -- Access control, Company business management, Risk management, Privacy issue, Business, News, opinion and commentary
Abstract

The Executive Women's Forum on Information Security, Risk Management & Privacy (EWF) announces their three newest board members, Brenda Bjerke, Jane Harper and Diana Kelley! FLEMINGTON, N.J., Nov. 2, 2021 [...]

Published
2021

35. Annual Ruth Chris Event - Understanding Captive Centric Corporate Risk Management and Insurance Strategies

Subjects
Eli Lilly and Co. -- Management, Risk management, Captive insurance companies, Pharmaceutical industry, Company business management, Risk management, General interest, News, opinion and commentary
Abstract

Morristown: Financial Executives International has issued the following press release: Annual Ruth Chris Event - Understanding Captive Centric Corporate Risk Management and Insurance Strategies October 28, 2021 | 5:30 PM [...]

Published
2021

36. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Author

Nathan, David M., Buse, John B., Davidson, Mayer B., Ferrannini, Ele, Holman, Rury R., Sherwin, Robert, and Zinman, Bernard

Subjects
Merck & Company Inc. -- Management, Pfizer Inc. -- Management, Novartis AG -- Management, Eli Lilly and Co. -- Management, Diabetes therapy, Thiazolidinediones, Type 2 diabetes -- Development and progression -- Care and treatment, Hyperglycemia -- Development and progression -- Care and treatment, Algorithms, Pharmaceutical industry, Company business management, Algorithm, Health, American Diabetes Association -- Management
Abstract

The consensus algorithm for the medical management of type 2 diabetes was published in August 2006 with the expectation that it would be updated, based on the availability of new [...]

Published
2009

37. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

38. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

39. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

40. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

41. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

42. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

43. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

44. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

45. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

46. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

47. Eli Lilly and Company UK

Subjects
Eli Lilly and Co. -- Management, Olaratumab, Ixekizumab, Pharmaceutical industry, Pemetrexed, Adalimumab, Medical economics, Partnerships, Production management, Company business management, Business, international, Olumiant (Medication), Jardiance (Medication), Basaglar (Medication), Trulicity (Medication), Forteo (Medication), Verzenio (Medication), Cialis (Medication), Taltz (Medication), Lartruvo (Medication)
Abstract

Founded by Eli Lilly in 1876, we are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has [...]

Published
2019

48. Working hand-in-hand to manage pharmacy costs: Utah's innovative use of the Behavioral Pharmacy Management program

Subjects
Eli Lilly and Co. -- Management, Drugstores, Pharmacy, Pharmaceutical industry, Health, Health care industry, Psychology and mental health, Company business management, Management
Abstract

Most states' Medicaid programs are under financial pressure as the number of enrollees fluctuates, federal matching funds are threatened perennially, prices of pharmaceuticals steadily rise based on a number of [...]

Published
2006

49. Eli Lilly expansion has potential to create new jobs in Cork

Subjects
Eli Lilly and Co. -- Management, Job creation, Pharmaceutical industry, Company business management, Business, international, Law
Abstract

Pharma company Eli Lilly has officially opened the extension to its existing biotechnology manufacturing site in Kinsale, in a move that has the potential to create a substantial number of [...]

Published
2021

50. Nutrition therapy recommendations for the management of adults with diabetes

Author

Evert, Alison B., Boucher, Jackie L., Cypress, Marjorie, Dunbar, Stephanie A., Franz, Marion J., Mayer-Davis, Elizabeth J., Neumiller, Joshua J., Nwankwo, Robin, Verdi, Cassandra L., Urbanski, Patti, and Yancy, William S., Jr.

Subjects
Eli Lilly and Co. -- Management, Cholesterol, Diabetes -- Diet therapy, Nutrition, Adults, Diabetics -- Diet therapy, Food habits, Pharmaceutical industry, Company business management, Health, American Diabetes Association -- Management
Abstract

A healthful eating pattern, regular physical activity, and often pharmacotherapy are key components of diabetes management. For many individuals with diabetes, the most challenging part of the treatment plan is [...]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results